RPS urges social media to ban content promoting or selling DNP

Date:

Share post:

The Royal Pharmaceutical Society (RPS) has called for a ‘firm commitment’ to prosecuting those making profits through the sale of DNP (2,4-Dinitrophenol).

It has also urged the social media companies to ‘remove content promoting or selling DNP to further reduce harm’.

Legislation to regulate DNP will come into effect on 1 October 2023. On Monday (23 January) it was announced that DNP will be included in the 1972 Poisons Act.

President of RPS Professor Claire Anderson said: “DNP is unfit for human consumption and its main use is in the manufacture of explosives and pesticides. It is sold by unscrupulous dealers to vulnerable individuals wanting to lose weight but has a dangerous effect on the metabolism and has led to 32 deaths since 2007 in those taking it as a ‘diet drug’.

“Including DNP in the Poisons Act is a positive move as it will restrict its availability, but what’s really needed is an outright ban to reduce the risk to the public. Australia has already classified DNP as a substance of such a danger to health as to warrant prohibition of sale and we’d like the UK to follow suit.

“We are concerned that DNP is still in circulation and want to see a firm commitment to prosecuting those who make profits from it. We also call on social media companies to remove content promoting or selling DNP to further reduce harm.”

 

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...